16 studies found for:    scFv
Show Display Options
Rank Status Study
1 Terminated Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
Conditions: Breast Cancer;   Colorectal Cancer;   Gastric Cancer;   Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes;   Biological: aldesleukin;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Other: laboratory biomarker analysis;   Other: pharmacological study
2 Completed IMCgp100 in Advanced Unresectable Melanoma
Conditions: Melanoma;   Advanced Disease;   Unresectable
Intervention: Drug: IMCgp100 injection
3 Active, not recruiting Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Multiple Myeloma;   Acute Myeloid Leukaemia;   Myelodysplastic Syndrome
Intervention: Biological: Anti-LeY- scFv-CD28-ζ vector,.
4 Completed Study of Intra-articular DLX105 Applied to Patients With Severely Painful Osteoarthritis of the Knee
Condition: Osteoarthritis
Interventions: Biological: DLX105, a single-chain (scFv) antibody fragment against TNF-alpha;   Drug: Placebo
5 Not yet recruiting Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma
Condition: Lymphoma
Intervention: Biological: DNA Vaccine
6 Completed Ocular Biodistribution Study for Topically Applied ESBA105
Condition: Cataract
Intervention: Drug: Placebo
7 Recruiting Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia
Conditions: Patients With B Cell ALL, Relapsed or Refractory, With no Available;   Curative Treatment Options (Such as Autologous or Allogeneic Stem Cell;   Transplantation) Who Have Limited Prognosis (> 12 Weeks Survival Expectancy);   With Currently Available Therapies.
Intervention: Biological: CART-19 cells
8 Recruiting Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Condition: Malignant Melanoma
Intervention: Drug: IMCgp100
9 Completed Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis
Condition: Anterior Uveitis
Intervention: Biological: ESBA105
10 Completed A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours
Condition: Advanced Solid Tumours
Intervention: Drug: L19IL2
11 Recruiting CART-19 for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Biological: CART-19 T cells
12 Recruiting CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
Conditions: B Cell Lymphoma;   B Cell Leukemia
Intervention: Biological: Autologous 3rd generation CD19-targeting CAR T cells
13 Not yet recruiting Assessment of Toxicity of the Immunocytokine L19-IL2 Administered Directly After the Course of Stereotactic Ablative Body Radiotherapy in Patients Suffering From Oligometastatic Solid Tumour.
Condition: Solid Tumour
Intervention: Drug: L19-IL2
14 Completed Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28
Condition: Malignant Melanoma
Interventions: Drug: rM28;   Drug: autologous PBMCs
15 Recruiting Autologous Redirected RNA Meso-CIR T Cells
Condition: Malignant Pleural Mesothelioma
Intervention: Biological: Autologous T cells
16 Completed Genetically Engineered Lymphocyte Therapy in Treating Patients With B-Cell Leukemia or Lymphoma That is Resistant or Refractory to Chemotherapy
Conditions: Hematopoietic/Lymphoid Cancer;   Adult Acute Lymphoblastic Leukemia in Remission;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Other: laboratory biomarker analysis;   Genetic: polymerase chain reaction;   Genetic: reverse transcriptase-polymerase chain reaction;   Biological: anti-CD19-CAR retroviral vector-transduced autologous T cells;   Biological: genetically engineered lymphocyte therapy

Indicates status has not been verified in more than two years